PTIX
NASDAQProtagenic Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.73+0.00 (+0.00%)
2026-03-232026-06-25
News · 26 weeks9-100%
2025-12-282026-06-21
Mix290d
- Market2(100%)
Latest news
25 items- NEWSProtagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations PartnerNEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric disorders, today announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by regulatory affairs veteran Dr. Eric Floyd, Ph.D., MBA, as Regulatory Affairs Advisor, and DanforthHealth, a premier life science operational consulting firm, to establish institutional-grade operational processes and infrastructure. Together, these engagements reflect Protagenic's deliberate, lean operati
- NEWSProtagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related neuropsychiatric disorders, today announced the appointment of Bill Nichols Jr. as President. This strategic leadership addition, combined with a thoughtful optimization of the Company's management structure, sharpens focus and resources on advancing its lead candidate, PT00114 - positioning Protagenic for accelerated clinical progress and long-term value creation for patients and shareholders alike.Mr. Nichols brings more than two decades of senior leadership experience spanning strategy,
- NEWSProtagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114NEW YORK CITY, NY / ACCESS Newswire / March 17, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related neuropsychiatric disorders, today announced the closing of a settlement and separation related to its prior Phytanix Bio acquisition. The transaction simplifies Protagenic's capital structure, materially reducing liabilities and sharpens the Company's operating focus on PT00114.At the common-share level, the
- NEWSProtagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture MarketMove strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related disorders, including treatment-resistant depression and anxiety, today announced that its common stock has been upgraded from OTC Pink to the OTCQB® and has commenced trading on OTCQB under the symbol "PTIX."The OTCQB is a recognized public market for developing companies that meet defined reporting, management certification and bid price stand
- SECSEC Form 10-Q filed by Protagenic Therapeutics Inc.10-Q - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECProtagenic Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECProtagenic Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECSEC Form NT 10-Q filed by Protagenic Therapeutics Inc.NT 10-Q - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECProtagenic Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- NEWSResults from Phase 1 Multiple-Dose Study of PT00114Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing therapeutics that target the biology of chronic stress and its downstream psychiatric and neurologic effects, today reported positive topline safety results from its Phase 1 Multiple Dose (MD) study of PT00114.PT00114 is a synthetic analogue of a naturally occurring brain peptide thought to be involved in restoring homeostasis following prolonged exposure to stress. Its mechanism of action-rooted in rebalancing dysfuncti
- SECSEC Form DEF 14A filed by Protagenic Therapeutics Inc.DEF 14A - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- NEWSProtagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance NoticeNEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications Staff (the "Staff") indicating that the Company is not in compliance with Nasdaq Listing Rules 5550(b)(1) (minimum stockholders' equity) and 5250(c)(1) (timely filing of periodic reports).The Staff determined that, based on the stockholders' equity reported in the Company's Transition Report on Form 10-QT for the period ended June 30, 2025, the Company no longer satisfies the minimum $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1). The Staff also notified t
- SECSEC Form 10-Q filed by Protagenic Therapeutics Inc.10-Q - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECProtagenic Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECSEC Form NT 10-Q filed by Protagenic Therapeutics Inc.NT 10-Q - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- NEWSProtagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD StudyNEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and neurodegenerative disorders, today announced the successful completion of enrollment and dosing in its Multiple Ascending Dose (MAD) Phase 1 study evaluating its lead compound, known as PT00114. The study, conducted in healthy volunteers, was designed to assess the safety and tolerability profile of PT00114 following multiple doses over time. With all healthy volunteers now dosed, the company has achieved a milestone in the clinical development of its proprietary peptide-based therapeutic."We've
- SECProtagenic Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECProtagenic Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECSEC Form 424B5 filed by Protagenic Therapeutics Inc.424B5 - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- INSIDERNew insider Evans Barrett claimed ownership of 787 units of Preferred Stock Series C, claimed ownership of 131,034 units of Preferred Stock Series C-1, claimed ownership of 6,498 units of Preferred Stock Series D and claimed ownership of 16,233 shares (SEC Form 3)3 - Protagenic Therapeutics, Inc.\new (0001022899) (Issuer)
- SECAmendment: Protagenic Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECSEC Form 10-QT filed by Protagenic Therapeutics Inc.10-QT - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECAmendment: Protagenic Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- SECProtagenic Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Registrant's Certifying Accountant, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)
- NEWSProtagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq ComplianceDelay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced that it expects to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 in the near future, following a delay attributable to the completion of merger-related consolidation of financial statements, including purchase accounting adjustments, pro forma financial information, and related disclosures. While the Company anticipates this delay to be brief, there can be no assurance as to the definitive timing of the filing.Protagen
PTIX FAQ
6 questionsWhat does Protagenic Therapeutics Inc. do?
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.Where does PTIX stock trade?
Protagenic Therapeutics Inc. (PTIX) is listed on NASDAQ.What sector and industry is PTIX in?
Protagenic Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PTIX?
Protagenic Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $400.00 price target on 2021-10-29. Recent price targets cluster around $400.00.What companies are similar to PTIX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PTIX side-by-side with any of them on Quantisnow.How can I track PTIX on Quantisnow?
Quantisnow aggregates Protagenic Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTIX to receive live email and push alerts on every new disclosure.